In this issue:
Effect of cladribine on lymphocyte dynamics in patients with relapsing MS
Immune profiling of a patient with alemtuzumab-associated PML
Effect of age at puberty on risk of MS
Childhood MS is associated with reduced brain volumes
Phase II trial of AHSCT for treatment of refractory MS
A survey of risk tolerance to MS therapies
Prevalence of benign MS
Efficacy of cladribine in high disease activity patients with relapsing MS
Predictive validity of different NEDA definitions
Feasibility trial of flavonoid-rich cocoa for fatigue in RRMS
Please login below to download this issue (PDF)